IP Library Granted Patent US 8,153,597
Granted Patent B2
US 8,153,597 · App. 12/712,336 · Granted Apr 10, 2012

Modulators of the ABC transporter family and methods for their use

Assignee: Trustees of Dartmouth College
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,153,597
App. No.
12/712,336
Granted
Apr 10, 2012
Kind
B2
Abstract

An isolated factor derived from the bacterium Pseudomonas aeruginosa and confirmed by proteomics to be a protein that reduces expression of ABC transmembrane proteins and active fragments and mimetics thereof are provided. Also provided is a method for inhibiting expression of ABC transmembrane proteins in cells by administering to the cells the isolated factor or protein or active fragment thereof or a mimetic thereof. Such methods are useful in the enhancing delivery of small molecule therapeutic agents to the CNS and in treating cancers, particularly multidrug resistant cancers, and secretory diarrhea. In addition, compositions, methods for identifying compositions and methods for use of compositions that inhibit suppression of ABC transmembrane protein expression or reduce epoxide hydrolase activity by this factor are provided. Such compositions and methods are useful in treatment of cystic fibrosis.

Claims (5)

1. A method for modulating plasma membrane expression of an ATP-binding cassette (ABC) transmembrane protein in a cell comprising administering to the cell a composition that modulates plasma membrane expression of ABC transmembrane protein, said composition comprising:

(a) a cystic fibrosis transmembrane conductance regulator inhibitory factor protein of SEQ ID NO:1 or fragment of SEQ ID NO:1 which exhibits the same or similar plasma membrane expression of the ABC transmembrane protein modulating activity as SEQ ID NO:1; and

(b) a physiologically acceptable vehicle.

2. The method of claim 1 wherein the cell is a mammalian cell.

3. The method of claim 1 wherein the composition comprises the cystic fibrosis transmembrane conductance regulator inhibitory factor protein of SEQ ID NO:1.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 25, 2020
From: DARTMOUTH COLLEGE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 053311/0948 →
Continuity (5)
Division 11691595 · Mar 27, 2007
Continuation In Part 10575577 · May 24, 2006
Continuation PCTUS2004033874 · Oct 14, 2004
Provisional Application 60511609 · Oct 15, 2003
Related Publication 20100197593A1 · Aug 5, 2010